Family Medicine CME Disclosures & Objectives

Learning Objectives

Demonstrate an increase in your knowledge of clinical medicine.
Evaluate the appropriateness of clinical information as it applies to the care of your patients.
Demonstrate an improvement in your ability to make decisions that provide safe and effective medical care.
Recognize areas of personal strength and areas for growth in clinical knowledge.

Intended Audience

Physicians, residents, and physician assistants who are seeking to maintain and augment their knowledge in family medicine and/or who are preparing for their initial board certification or recertification.

Accreditation

The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Credit

The Massachusetts Medical Society designates this enduring material for a maximum of 330 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credit

This Enduring Material activity, NEJM Knowledge+ Family Medicine Board Review, has been reviewed and is acceptable for up to 330.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 02/01/2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Self-Assessment CME Credit

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 20.00 AAPA Category 1 Self-Assessment CME credits. Approval is valid for one year from 02/01/2020. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

You must answer questions correctly to receive AMA PRA Category 1 Credits™, AAFP Prescribed credits, and AAPA Category 1 Self-Assessment CME credits toward Certification Maintenance.

Six questions answered correctly are designated for 1 AMA PRA Category 1 Credit™, 1 AAFP Prescribed credit, and 1 AAPA Category 1 Self-Assessment CME credit.

CME Accreditation Term

Original Release Date: February 1, 2015
Review dates: 2015, 2016, 2017, 2018
Termination Date: February 1, 2021

Individual Disclosures

During their tenure with NEJM Knowledge+, the following planners, authors, and reviewers have disclosed the following relevant financial relationships with an ACCME-defined commercial interest.

Thomas M. Best, MD, PhD
– Consultant for Abbot and ZetrOZ

William Busse, MD
–   Advisory board for Merck
–   Consultant for Amgen, Novartis, GlaxoSmithKline, MedImmune, and Genentech
–   Data monitoring boards for Genentech and Boston Scientific
–   Study oversight committee for ICON

Andrew T. Chan, MD
– Consultant for Bayer Healthcare, Pfizer, Pozen, and Millennium Pharmaceuticals
– Speakers bureau for Millennium Pharmaceuticals

Vincent W. Chiang, MD
– Financial interest in and advisory board member for AugMI Labs

Jean M. Connors, MD
–   Honoraria from Pfizer
–   Consultant for Proteostasis Therapeutics
–   Scientific advisory board for Portola Pharmaceuticals

Kelly M. Cordoro, MD
– Consulting for Anacor Pharmaceuticals
– Scientific steering committee for Celgene

Peter D. Friedmann, MD, MPH
– Legal expert consultant for Endo Pharmaceuticals
– In-kind research support from Alkermes
– Scientific advisory committee for Indivior

Rajesh T. Gandhi, MD
–   Scientific advisory board for Gilead and Merck
–   Grant support from Tibotec (Janssen Therapeutics), Abbott, ViiV Healthcare, Gilead, Merck, and Theratechnologies
–   Consultant for Theratechnologies

James E. Gern, MD
– Consultant for Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline, Boehringer Ingelheim, MedImmune AstraZeneca, and Merck
– Grant support from GlaxoSmithKline and Merck

Emily M. Godfrey, MD, MPH
– Speakers’ bureaus for Merck Pharmaceuticals and Bayer Women’s Health
– Consultant for Teva Women’s Health

Jason Robert Gotlib, MD
–   Clinical trial research funding from Novartis, Promedior, Incyte, CTI Biopharma, Gilead, Seattle Genetics, and Pharmacyclics
–   Study steering committee member, advisory board member, and receipt of honoraria from Novartis
–   Advisory board member and receipt of honoraria from Incyte

Ole-Petter Riksfjord Hamnvik, MB BCh BAO, MMSc
– Consultant for Fusion Pharmaceuticals

Elizabeth Harrison, MD
– Financial interest in Pfizer, Merck, and Express Scripts

Simon M. Helfgott, MD
– Consultant for AbbVie and Genentech

James V. Hennessey, MD
– Consultant for Akrimax and AbbVie

Mihir M. Kamdar, MD
– Scientific advisory board for Amorsa Therapeutics
– Expert advisory panel for Collegium Pharmaceuticals
– Consultant for Vivtex

Amel Karaa, MD
–   Consulting fees from Akros Pharma, Concert, Alexion, Lumleian, and Mitobridge
–   Grant support, reimbursement for travel, and consulting payments from Stealth BioTherapeutics and Shire
–   Grant support, consulting fees, reimbursement for travel, and honoraria from Sanofi Genzyme
–   Grant support and reimbursement for travel from Reata Pharmaceuticals and Protalix BioTherapeutics

Eli Miloslavsky, MD
– Fellowship in 2012–2013 from Genentech

Mizuho S. Mimoto, MD, PhD
– Spouse is an employee/stockholder for AbbVie

Paul A. Monach, MD
– Grant support from Genentech

Christopher J. Moran, MD
– Grant support from Allergan

Alan C. Moss, MD
– Consultant for Janssen Pharmaceutical Companies of Johnson & Johnson, Theravance Biopharma, Seres Therapeutics, Boehringer Ingelheim, Pfizer, Gilead, and Mallinckrodt Pharmaceuticals
– Grant research/support from Pfizer and Boehringer Ingelheim

Leigh C. Reardon, MD
– Consultant and speakers bureau for Actelion

Richa Chibbar, MD
– Consultant for Ferring Pharmaceuticals and AbbVie

Shari S. Rogal, MD, MPH
– Grant support from Gilead

Misha A. Rosenbach, MD
– Consultant for Celgene

Paul E. Sax, MD
– Consultant for Bristol-Myers Squibb, GlaxoSmithKline, Merck, Janssen Pharmaceutical Companies of Johnson & Johnson, and Gilead
– Grant support from Bristol-Myers Squibb, GlaxoSmithKline, Merck, and Gilead

Marvin I. Schwarz, MD
– Consultant for Boehringer Ingleheim, InterMune, and Merck

Bradford Shingleton, MD
– Consultant for Transcend Medical
– Grant research/support from Alcon

John I. Takayama, MD, MPH
– Financial interest in Omnicell

Derrick J. Todd, MD, PhD
– Consultant for Genentech, Kiniksa Pharmaceuticals, and Regeneron

Avram Z. Traum, MD
– Consultant for Alexion Pharmaceuticals

Andrew A. Wagner, MD
– Consultant for BK ultrasound

Melissa B. Weimer, DO
– Advisory role with Alkermes

James L. Zehnder, MD
– Grant research/support from Novartis

None of the other individuals in a position to control the activity have any relevant financial relationships with commercial interests to report. The complete list of contributors can be found here.

Conflict of Interest Resolution

The Department of Continuing Education and Certification (DCEC) of the Massachusetts Medical Society has reviewed the appropriate documentation provided by the above planners, authors, and reviewers. Any potential conflicts of interest have been identified and resolved using DCEC processes for conflict management and resolution. For more information about DCEC processes for COI management, please contact the DCEC at continuingeducation@mms.org.

Disclosure of Commercial Support

No commercial support was received for this activity.

Medium or Combination of Media Used

This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.

Estimated Time to Complete the Educational Activity

One hour for every 6 questions answered correctly.

Bibliography

Each clinical vignette includes citations and references.

Hardware/Software Requirements

Windows

Google Chrome 30+, Safari 5.0+, Internet Explorer 11.0+, Mozilla Firefox 10.0+, Microsoft Edge
Recommended: Google Chrome 39+, Safari 7+, Internet Explorer 11, or Firefox 32+
Windows 7 (32-bit and 64-bit), Windows 8+. Windows 7+ is recommended.
Minimum 1 GB of RAM but 2 GB or greater is recommended
2.33 GHz or faster x86-compatible processor, or Intel® Atom™ 1.6 GHz or faster processor for netbooks
Display resolution: 1024 × 768 or better

Mac OS

Google Chrome 14+, Safari 5.0+, Mozilla Firefox 12.0+
Recommended: Google Chrome 39+, Safari 7+, or Firefox 32+
Mac OS X v10.6+
Minimum 1 GB of RAM but 2 GB or greater is recommended
Intel Core™ Duo 1.33GHz or faster processor
Display resolution: 1024 × 768 or better

Mobile/Tablet

NEJM Knowledge+ apps are available for iOS and Android smartphones and tablets; Android phones may access NEJM Knowledge+ through our mobile-optimized browser version.

iOS devices running OS 8+(includes iPhone and iPad devices).
Android version 4+ (includes smartphones and tablets). Android version 5+ is recommended. Note: Android phones will also support the browser version of each product (Chrome recommended).

Contact Information

For all questions and comments, please contact NEJM Knowledge+ by email at knowledgeplussupport@nejm.org or call toll-free +1-855-318-9303 (within the USA and Canada) or +1-781-434-7998.

Policy on Privacy and Confidentiality

Read our Privacy Policy.